Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cardionet Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cardionet Inc : CardioNet, Inc. to Acquire CardioCORE Lab, Inc. for $23.5 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/06/2012 | 02:10pm CEST

CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that it has entered into a definitive merger agreement with cardioCORE Lab, Inc., a leading centralized cardiac testing laboratory with locations near Washington, D.C., San Francisco, CA and London, UK.

The total consideration to be paid by CardioNet will be $23.5 million. At its option, CardioNet may pay up to $3.5 million of the total consideration in the form of common stock. The transaction, subject to customary closing conditions, is expected to close in the third quarter of 2012.

Joseph Capper, President and Chief Executive Officer of CardioNet, commented: "The acquisition of cardioCORE is an important step toward achieving our previously announced strategic objectives. We are now in an excellent position to leverage our current technology and monitoring infrastructure into a large and growing adjacent market. Additionally, this acquisition goes a long way in mitigating some of our revenue concentration and reimbursement risk. We are truly becoming a full-service cardiac monitoring company."

Jennifer Cotteleer, President and Chief Executive Officer of cardioCORE, commented: "We are looking forward to joining forces with CardioNet to continue the development of products and services that support excellence in cardiac monitoring for clinical research and patient care. The combined strength of the companies creates the platform to produce ongoing innovation in support of this goal."

cardioCORE is expected to generate $19.0 to $20.0 million in revenue and $3.5 to $4.0 million in EBITDA for the full year 2012. CardioNet will provide additional information regarding the expected financial impact of the transaction on its second half results during its earnings conference call scheduled for August 8, 2012.

About CardioNet

CardioNet is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient TelemetryTM (MCOTTM). More information can be found at http://www.cardionet.com.

About cardioCORE

cardioCORE has provided superior centralized cardiac testing services to the pharmaceutical industry for 18 years. Services include centralized electrocardiography (ECG), Holter monitoring, ambulatory blood pressure monitoring (ABPM), echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development, and statistical analysis. The Company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway? and CardioPortal?. cardioCORE is headquartered in Rockville, Maryland, with offices in South San Francisco, California and London, England. www.cardiocore.com

Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company's future. These statements may be identified by words such as "expect," "may," "anticipate," "possible," "estimate," "potential," "intend," "plan," "believe," "forecast," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the effect of the cardioCORE acquisition on our business operations and successful integration into our business,financial results, effectiveness of our efforts to address operational initiatives, including cost savings initiatives that affect our business, changes to insurance coverage, relationships with our government and commercial payors and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services and patent protection, adverse regulatory action and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CardioNet, Inc.
Heather C. Getz, 800-908-7103
Investor Relations
investorrelations@cardionet.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDIONET INC
08/30 BIOTELEMETRY : announces CE mark approval of Holter analysis software
08/29 BioTelemetry, Inc. announces CE mark approval of Holter analysis software
08/23 BIOTELEMETRY, INC. : Other Events (form 8-K)
08/23 BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technolo..
08/03 BIOTELEMETRY : Management's Discussion and Analysis of Financial Condition and R..
08/03 BIOTELEMETRY : posts 2Q profit
08/02 BIOTELEMETRY, INC. : Results of Operations and Financial Condition, Financial St..
08/02 BioTelemetry, Inc. Reports Second Quarter 2016 Financial Results
07/27 BIOTELEMETRY : Announces FDA Approval of Its Next Generation Device, the MCOT Pa..
07/26 BioTelemetry, Inc. to Release Second Quarter 2016 Earnings Results on August ..
More news
Sector news : Healthcare Facilities & Services - NEC
09/16 FTSE falls as banking stocks lose ground
09/14DJBusiness Watch -- WSJ
09/13DJUNITEDHEALTH : Optum Unit to Oversee Quest Diagnostics' Billing Processes
09/13DJUNITEDHEALTH : Optum Unit to Oversee Quest Diagnostic's Billing Processes
09/05DJFRESENIUS : to Buy Spanish Hospital Group Quironsalud for 5.76 Billion Euros
More sector news : Healthcare Facilities & Services - NEC
Advertisement
Financials ($)
Sales 2016 210 M
EBIT 2016 24,8 M
Net income 2016 18,0 M
Debt 2016 1,00 M
Yield 2016 -
P/E ratio 2016 31,20
P/E ratio 2017 24,96
EV / Sales 2016 2,50x
EV / Sales 2017 2,45x
Capitalization 525 M
More Financials
Technical analysis trends CARDIONET INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 3
Average target price 25,3 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph H. Capper President, Chief Executive Officer & Director
Kirk E. Gorman Chairman
Heather C. Getz Chief Financial Officer & Senior Vice President
Daniel M. Wisniewski Senior Vice President-Technical Operations
Wayne M. Derkac Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIONET INC525
HCA HOLDINGS INC12.55%28 823
FRESENIUS MEDICAL CARE..3.60%28 112
LABORATORY CORP. OF AM..11.12%14 055
DAVITA INC-4.60%13 759
UNIVERSAL HEALTH SERVI..2.88%11 975
More Results